{
    "clinical_study": {
        "@rank": "105928", 
        "arm_group": [
            {
                "arm_group_label": "Part A: MK-5172 + MK-8742 + RBV", 
                "arm_group_type": "Experimental", 
                "description": "During Part A of the study, GT2 participants will receive 100 mg MK-5172 + 50 mg MK-8742 + standard weight-based dosing of RBV for 12 weeks."
            }, 
            {
                "arm_group_label": "Part B: MK-5172 + RBV", 
                "arm_group_type": "Experimental", 
                "description": "During Part B of the study, GT2 participants will receive 100 mg MK-5172 + standard weight-based dosing of RBV for 12 weeks."
            }, 
            {
                "arm_group_label": "Part B: MK-5172 + MK-8742 + RBV", 
                "arm_group_type": "Experimental", 
                "description": "During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg MK-5172 + 50 mg MK-8742 + standard weight-based dosing of RBV for 12 weeks."
            }, 
            {
                "arm_group_label": "Part B: MK-5172 + MK-8742", 
                "arm_group_type": "Experimental", 
                "description": "During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg MK-5172 + 50 mg MK-8742 for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-site, open-label trial evaluating the safety and efficacy of 100 mg of\n      MK-5172 (a second-generation protease inhibitor) used in combination with/or without 50 mg\n      of MK-8742 (an NS54A inhibitor) and/or ribavirin (RBV) in treating non-cirrhotic\n      treatment-na\u00efve (TN) participants with chronic genotype (GT) 2, 4, 5, and 6 hepatitis C\n      infection."
        }, 
        "brief_title": "Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Parts A and B:\n\n          -  Body weight \u226550 kg (111 lbs) and \u2264 125 kg (275 lbs)\n\n          -  Has absence of cirrhosis\n\n          -  Agrees to use two acceptable methods of birth control from at least 2 weeks prior to\n             Day 1 and continue until at least 6 months after last dose of study drug, or longer\n             if dictated by local regulations (for female subject who is of childbearing potential\n             or male subject with female sexual partner who is of childbearing potential).\n\n        Part A only:\n\n          -  Has chronic HCV GT2 infection\n\n        Part B only:\n\n          -  Has chronic HCV GT2, GT4, GT5, or GT6 infection\n\n        Exclusion Criteria:\n\n        Parts A and B:\n\n          -  Is not treatment na\u00efve (participant has had previous treatment with any interferon,\n             RBV, approved or experimental direct acting antiviral(s), or other investigational\n             therapies for HCV)\n\n          -  Is determined to be coinfected with hepatitis B virus (HBsAg positive) or HIV\n\n          -  Has evidence of, or is under evaluation for, hepatocellular carcinoma (HCC)\n\n          -  Has a clinical diagnosis of substance abuse including the following specified drugs\n             within specified timeframes: Alcohol, intravenous drugs, inhalational, psychotropics,\n             narcotics, cocaine use, prescription or over-the-counter drugs (within 1 year of the\n             screening visit), is receiving opiate agonist substitution therapy (within 1 year of\n             screening visit), or excessive historic marijuana use\n\n          -  Has evidence of active or suspected malignancy, or a history of malignancy, within\n             the last 5 years\n\n          -  Female participant who is pregnant, lactating, expecting to conceive or donate eggs,\n             or is of childbearing potential and unwilling to commit to two methods of birth\n             control throughout treatment and after the completion of all treatment, or male\n             participant who is planning to impregnate or provide sperm donation or has a female\n             sexual partner of childbearing potential and is unwilling to commit to using a two\n             methods of birth control throughout treatment and after the completion of all\n             treatment\n\n          -  Has evidence or history of chronic hepatitis not caused by HCV, including but not\n             limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and\n             autoimmune hepatitis.\n\n          -  Has uncontrolled diabetes (documented HbA1c >8.5%)\n\n        Part A only:\n\n          -  Has non GT2 HCV infection\n\n        Part B only:\n\n          -  Has HCV infection with a genotype other than GT2, GT4, GT5 or GT6"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932762", 
            "org_study_id": "5172-047", 
            "secondary_id": "2013-002169-21"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A: MK-5172 + MK-8742 + RBV", 
                    "Part B: MK-5172 + RBV", 
                    "Part B: MK-5172 + MK-8742 + RBV", 
                    "Part B: MK-5172 + MK-8742"
                ], 
                "description": "100 mg every day (QD) orally", 
                "intervention_name": "MK-5172", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A: MK-5172 + MK-8742 + RBV", 
                    "Part B: MK-5172 + MK-8742 + RBV", 
                    "Part B: MK-5172 + MK-8742"
                ], 
                "description": "50 mg QD orally", 
                "intervention_name": "MK-8742", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A: MK-5172 + MK-8742 + RBV", 
                    "Part B: MK-5172 + RBV", 
                    "Part B: MK-5172 + MK-8742 + RBV"
                ], 
                "description": "Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Rebetol\u2122"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 4, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "From Treatment Week (TW) 1 to Follow-up Week (FW) 12 (up to 24 weeks)"
            }, 
            {
                "measure": "Percentage of Participants with Adverse Events (AEs), Serious AEs (SAEs), Drug-Related AE, Drug-Related SAE, or Discontinuation Due to AE", 
                "safety_issue": "Yes", 
                "time_frame": "From TW1 through FW 24 (up to 36 weeks)"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Australia", 
                "France", 
                "United Kingdom", 
                "Belgium", 
                "Spain", 
                "Israel"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to First Achievement of Undetectable HCV RNA", 
                "safety_issue": "No", 
                "time_frame": "From TW1 through FW 24 (up to 36 weeks)"
            }, 
            {
                "measure": "Percentage of Participants Achieving Undetectable HCV RNA", 
                "safety_issue": "No", 
                "time_frame": "From TW 1 through TW 12 (up to 12 weeks)"
            }, 
            {
                "measure": "Percentage of Participants Achieving HCV RNA <25 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "From TW 1 through TW 12 (up to 12 weeks)"
            }, 
            {
                "measure": "Percentage of Participants Achieving SVR4", 
                "safety_issue": "No", 
                "time_frame": "From TW1 through FW 4 (up to 16 weeks)"
            }, 
            {
                "measure": "Percentage of Participants Achieving SVR24", 
                "safety_issue": "No", 
                "time_frame": "From TW1 through FW 24 (up to 36 weeks)"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}